Mark T. Reding

Director
Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center
Minneapolis, Minnesota, United States

Presentation(s):

• PB0225 - High Bleed Control with a Single 225 µg/kg Eptacog Beta Dose in Adult and Adolescent Hemophilia A or B Persons with Inhibitors

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0261 - Investigating effectiveness and safety of extended dosing regimens of damoctocog alfa pegol in the real-world HEM-POWR study

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB1220 - Cardiovascular Risk Factors in a Large Multi-Institutional Cohort of Persons with Hemophilia

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT